Pucotenlimab, a recombinant humanised PDL1 inhibitor, was combined with MRG003, an antibody drug conjugate targeting epidermal growth factor receptor (EGFR) with an MMAE payload, in a Phase I/II trial and preliminary results demonstrated a response rate of up to 60% in the previously treated HNSCC cohort. Here, CD274 is linked to head and neck squamous cell carcinoma.